N

Nirsevimabe

Monoclonal antibody used as vaccine against RSV

Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus.

Nº Q111535760 ★

Comum · Saberes

Nirsevimabe

Monoclonal antibody used as vaccine against RSV

Texto em inglês

Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus.

Último preço

—

Preço mínimo

—

Mediana 7 d

—

Vendas 30 d

0

Faixa 30 d

—

Em circulação

0

Cotação

Ver tabela
Datamediana MínMáxvendas

Histórico de vendas

Última venda
—
Média 30 d
—
Mínima 30 d
—
Máxima 30 d
—
Vendas 7 d
0
Vendas 30 d
0

Ainda sem vendas.

Vendas anônimas: sem comprador nem vendedor. Os números contam só vendas entre jogadores.

Na Wikipédia

Texto em inglês Ainda não há artigo no seu idioma: trecho em inglês.

Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus. The most common side effects are rash, fever and injection site reactions (such as redness, swelling and pain where the injection is given). It was developed by AstraZeneca and Sanofi. Nirsevimab was approved for medical use in both the European Union and the United Kingdom in November 2022, in Canada in April 2023, and in the United States in July 2023.

Texto: Wikipédia em inglês, CC BY-SA 4.0. ·

Cartas próximas

Ver a ficha

Confirmação